Arterial hypertension is an oxidative stress, as a pathogenetic target for the treatment of chronic cerebrovascular insufficiency

Chukanova E.I.; Chukanova A.S.; Andrianov D.D.

doi:https://doi.org/10.17116/jnevro202512501184

Close metadata

Recommended articles:

Personal characteristics of patients with cerebral microangiopathy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3):51-56

The study of the behavioral reactions and duration of ultrasonic vocalization in rats from females stressed during pregnancy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3):117-123

Sleep deprivation and the development of oxidative stress in animal models. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3):124-129

Modern approaches to diagnosis and treatment of postinfectious asthenic syndrome in children. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4):42-52

The main mechanisms of development of cognitive impairment. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):13-18

The known and new ideas about the mechanism of action and the spectrum of effects of Mexidol. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):22-33

Therapeutic potential of quercetin and its derivatives against COVID-19. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):44-50

Prevalence of cerebrovascular diseases risk factors according to the cohort survey data in Bishkek, Kyrgyz Republic. Russian Journal of Preventive Medicine. 2025;(3):34-39

Associations between the gut microbiota-derived metabolites with the parameters of 24-hour ambulatory blood pressure monitoring in patients on maintenance hemodialysis. Russian Journal of Preventive Medicine. 2025;(3):96-102

Influence of physical therapy on intestinal microbiota, blood pressure control and systemic inflammation level: a randomized controlled study of 84 patients with arterial hypertension. Problems of Balneology, Physiotherapy and Exercise Therapy. 2025;(2):11-20

Abstract:

The increase in the development of arterial hypertension (AH), as the main modifiable risk factor for the development of acute and chronic cerebral circulatory insufficiency, often leading to a progressive decrease in cognitive status and physical activity, requires early detection and effective pathogenetic therapy. The breadth of therapeutic effects of the drug Mexidol (ethylmethylhydroxypyridine succinate) due to the multifactorial nature of its pathogenetic effects contributes to its widespread use. The safe profile of Mexidol use and the absence of drug interaction makes it relevant in the complex treatment of patients with cardiovascular diseases.

Keywords:

arterial hypertension

oxidative stress

cerebral circulatory insufficiency

cognitive functions

endothelial sensitivity

G-protein coupled receptor 91 (GPR91)

succinate

ethylmethylhydroxypyridine succinate

Mexidol

Authors:

Chukanova E.I.

Pirogov Russian National Research Medical University (Pirogov University)

ORCID: 0000-0002-3291-9615

Chukanova A.S.

Pirogov Russian National Research Medical University (Pirogov University)

ORCID: 0000-0003-0940-782X

Andrianov D.D.

Pirogov Russian National Research Medical University (Pirogov University)

ORCID: 0009-0000-6917-4277

Received:

19.12.2024

Accepted:

26.12.2024

Close metadata

References:

Roger VL, Go AS, Lloyd-Jones DM, et al; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics--2012 update: a report from the American Heart Association. Circulation. 2012;125(1):2-220. https://doi.org/10.1161/CIR.0b013e31823ac046
Maksimova MYu, Sazonova VYu. Risk factors for ischemic stroke in men and women aged 45-74 years. Nevrologiya, Neiropsikhiatriya, Psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2023;15(4):38-44. (In Russ.). https://doi.org/10.14412/2074-2711-2023-4-38-44
Hilal S, Mok V, Youn YC, et al. Prevalence, risk factors and consequences of cerebral small vessel diseases: data from three Asian countries. J Neurol Neurosurg Psychiatry. 2017;88(8):669-674. https://doi.org/10.1136/jnnp-2016-315324
Pallarés-Carratalá V, Ruiz-García A, Serrano-Cumplido A, et al. Prevalence Rates of Arterial Hypertension According to the Threshold Criteria of 140/90 or 130/80 mmHg and Associated Cardiometabolic and Renal Factors: SIMETAP-HTN Study. Medicina (Kaunas). 2023;59(10):1846. https://doi.org/10.3390/medicina59101846
Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC)and the European Society of Hypertension (ESH). Eur Heart J. 2018;39(33):3021-3104. https://doi.org/10.1093/eurheartj/ehy339
Vicario A, Coca A, Gasecki D, et al. Effects of antihypertensive treatment on cognitive decline. ESH Scientific Newsletter. 2019;20:73-79.
Forlenza O, Diniz B, Stella F, et al. Mild cognitive impairment (part 1):Clinical characteristics and predictors of dementia. Rev Bras Psiquiatr. 2013;35(2):178-185. https://doi.org/10.1590/1516-4446-2012-3503
Stijntjes M, Aartsen M, Taekema D, et al. Temporal relationship between cognitive and physical performance in middleaged to oldest old people. J Gerontol A Biol Sci Med Sci. 2017;72(5):662-668. https://doi.org/10.1093/gerona/glw133
Shi Y, Thrippleton M, Makin S, et al. Cerebral blood flow in small vessel disease: A systematic review and meta-analysis. J Cereb Blood Flow Metab. 2016;36(10):1653-1667. https://doi.org/10.1177/0271678X16662891
Ostroumova TM, Kochetkov AI. Brain and heart. Non nocere. Novyy Terapevticheskiy Zhurnal = Non Nocere. New Therapeutic Journal. 2022;(11):52-60. (In Russ.).
Kasatkin DS. A neurovascular unit as a point of action of some vasoactive and neuroprotective drugs. S.S. Korsakov Journal of Neurology and Psychiatry. 2012;112(9):103-107. (In Russ.).
Hawkins BT, Davis TP. The blood-brain barrier/neurovascular unit in health and disease. Pharmacol Rev. 2005;57:173-185. https://doi.org/10.1124/pr.57.2.4
Gusev EI, Chukanova EI, Chukanova AS. Chronic cerebrovascular insufficiency (risk factors, pathogenesis, clinic, treatment).M. 2019. (In Russ.).
Eelen G, de Zeeuw P, Simons M, et al. Endothelial cell metabolism in normal and diseased vasculature. Circ Res. 2015;116(7):1231-1244. https://doi.org/10.1161/CIRCRESAHA.116.302855
Savoia C, D’Agostino M, Lauri F, et al. Angiotensin type 2 receptor in hypertensive cardiovascular disease. Curr Opin Nephrol Hypertens. 2011;20:125-132. https://doi.org/10.1097/MNH.0b013e3283437fcd
Weiss N, Miller F, Cazaubon S, et al. The bloodbrain barrier in brain homeostasis and neurological diseases. Bioch Biophys Acta. 2009;1788:842-857. https://doi.org/10.1016/j.bbamem.2008.10.022
Levin OS. Dyscirculatory encephalopathy. The method of settlement. M. 2010. (In Russ.).
Chukanova EI, Chukanova AS, Daniyalova ND. Cerebral venous disorders: diagnosis, clinical features. Nevrologiya, Neiropsikhiatriya, Psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2014;6(1):89-94. (In Russ.). https://doi.org/10.14412/2074-2711-2014-1-89-94
Gusev EI, Skvortsova VI. Cerebral ischemia. M.: Medicine. 2001. (In Russ.).
De Deyn PP, Reuck JD, Deberdt W, et al. Treatment of acute ischemic stroke with piracetam. Members of the Piracetam in Acute Stroke Study (PASS) Group. Stroke. 1997;28(12):2347-2352. https://doi.org/10.1161/01.str.28.12.2347
Goldstein LB, Adams R, Becker K, et al. Primary prevention of ischemic stroke: A statement for healthcare professionals from the Stroke Council of the American Heart Association. Stroke. 2001;32(1):280-299. https://doi.org/10.1161/01.str.32.1.280
Wardlaw JM, Smith EE, Biessels GJ, et al; STandards for ReportIng Vascular changes on nEuroimaging (STRIVE v1). Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol. 2013;12(8):822-838. https://doi.org/10.1016/S1474-4422(13)70124-8
Touyz RM, Rios FJ, Alves-Lopes R, et al. Oxidative Stress: A Unifying Paradigm in Hypertension. Can J Cardiol. 2020;36(5):659-670. https://doi.org/10.1016/j.cjca.2020.02.081
Iadecola C. Mechanisms of Cerebral Ischemic Damage. In: Walz, W. (eds) Cerebral Ischemia. Cont Neuroscience Humana Press, Totowa, NJ. 1999;3:33. https://doi.org/10.1007/978-1-59259-479-5_1
Wang Y, Chang CF, Morales M, et al. Bone morphogenetic protein-6 reduces ischemia-induced brain damage in rats. Stroke. 2001;32(9):2170-2178. https://doi.org/10.1161/hs0901.095650
Gomazkov OA. Neurotrophic regulation and brain stem cells. M.: Medicine. 2006;330. (In Russ.).
Gomazkov OA. Brain aging and neurotrophic therapy. M.: ICAR. 2011. (In Russ.).
Zhou J, Callapina M, Goodall GJ, et al. Functional integrity of nuclear factor kappaB, phosphatidylinositol 3’-kinase, and mitogen-activated protein kinase signaling allows tumor necrosis factor alpha-evoked Bcl-2 expression to provoke internal ribosome entry site-dependent translation of hypoxia-inducible factor 1alpha. Cancer Res. 2004;64(24):9041-9048. https://doi.org/10.1158/0008-5472.CAN-04-1437
Deen PM, Robben JH. Succinate receptors in the kidney. J Am Soc Nephrol. 2011;22(8):1416-1422. https://doi.org/10.1681/ASN.2010050481
Robben JH, Fenton RA, Vargas SL, et al. Localization of the succinate receptor in the distal nephron and its signaling in polarized MDCK cells. Kidney Int. 2009;76(12):1258-1267. https://doi.org/10.1038/ki.2009.360
Chen T, Maevsky EI, Uchitel ML. Maintenance of homeostasis in the aging hypothalamus: the central and peripheral roles of succinate. Front Endocrinol (Lausanne). 2015;6(7):1-11. https://doi.org/10.3389/fendo.2015.00007
Gahr M, Connemann BJ, Schonfeldt-Lecuona CJ, et al. Succinic semialdehyde dehydrogenase deficiency: an inheritable neurometabolic disease. Fortschritte Neurol Psychiatr. 2013;81(3):154-161. https://doi.org/10.1055/s-0032-1330544
Okovity SV, Radko SV, Shustov EB. Succinate receptors (SUCNR1) as a promising target of pharmacotherapy. Chemico-Pharmaceutical Journal. 2015;49(9):4-7. (In Russ.). https://doi.org/10.30906/0023-1134-2015-49-9-3-7
Ariza AC, Deen PM, Robben JH. The succinate receptor as a novel therapeutic target for oxidative and metabolic stress-related conditions. Front Endocrinol. 2012;3(22):1-8. https://doi.org/10.3389/fendo.2012.00022
He W, Miao F J-P, Lin D C-H, et al. Citric acid cycle intermediates as ligands for orphan G-protein-coupled receptors. Nature. 2004;429(6988):188-193. https://doi.org/10.1038/nature02488
Taniguchi H, Anacker C, Wang O, et al. Protection by vascular prostaglandin E2 signaling in hypoxic-ischemic encephalopathy. Exp Neurol. 2014;255:30-37. https://doi.org/10.1016/j.expneurol.2014.02.012
Burns PA, Wilson DJ. Angiogenesis mediated by metabolites is dependent on vascular endothelial growth factor (VEGF). Angiogenesis. 2003;6(1):73-77. https://doi.org/10.1023/A:1025862731653
Blad CC, Tang C, Offermann S. G protein-coupled receptors for energy metabolites as new therapeutic targets. Review Nat Rev Drug Discov. 2012;11(8):603-619. https://doi.org/10.1038/nrd3777
Naldini A, Carraro F. Role of inflammatory mediators in angiogenesis. Curr Drug Targets Inflamm Allergy. 2005;4(1):3-8. https://doi.org/10.2174/1568010053622830
Voronina TA. Mexidol: the spectrum of pharmacological effects. S.S. Korsakov Journal of Neurology and Psychiatry. 2012;112(12):86-90. (In Russ.).
Yakusheva EN, Mylnikov PYu, Chernykh IV, Shchulkin AV. Mexidol effect on the factor induced by hypoxia HIF-1α expression in the rat cerebral cortex in ischemia. S.S. Korsakov Journal of Neurology and Psychiatry. 2017;117(10):87-91. (In Russ.). https://doi.org/10.17116/jnevro201711710187-91
Yakusheva EN, Mylnikov PYu, Chernykh IV, et al. An effect of mexidol on the expression of the transcription factor Nrf2 in the rat cerebral cortex in ischemia. S.S. Korsakov Journal of Neurology and Psychiatry. 2018;118(5):64-68. (In Russ.). https://doi.org/10.17116/jnevro20181185164
Chukanova EI, Chukanova AS. Efficacy and safety of the drug mexidol FORTE 250 as part of sequential therapy in patients with chronic ischemia of the brain. S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(9):39-45. (In Russ.). https://doi.org/10.17116/jnevro201911909139
Tolkacheva VV, Kazakhmedov ER, Kobalava ZD, et al. Effect of Mexidol on the quality of life and functional status of patients with chronic cerebral ischemia and chronic heart failure with reduced left ventricular ejection fraction. Russian Journal of Cardiology and Cardiovascular Surgery. 2021;14(1):80-89. (In Russ.). https://doi.org/10.17116/kardio20211401180
Antipenko EA, Shulyndin AV, Belyakov KM. Neurometabolic therapy of mild cognitive impairment in patients with chronic cerebral ischemia. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;124(3):42-51. (In Russ.). https://doi.org/10.17116/jnevro202412403142
Fedin AI, Zaharov VV, Tanashyan MM, et al. Results of an international multicenter, randomized, double-blind, placebo-controlled study assessing the efficacy and safety of sequential therapy with Mexidol and Mexidol FORTE 250 in patients with chronic brain ischemia (MEMO). S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(11):7-16. (In Russ.). https://doi.org/10.17116/jnevro20211211117
Zakharov VV, Ostroumova OD, Kochetkov AI, et al. International multicenter randomized double-blind placebo-controlled study assessing the efficacy and safety of sequential therapy with Mexidol and Mexidol FORTE 250 in patients with chronic brain ischemia (MEMO): subanalysis in patients with arterial hypertension. Russian Journal of Preventive Medicine. 2024;27(10):72-83. (In Russ.). https://doi.org/10.17116/profmed20242710172
Martynov AI, Tanashyan MM, Malyavin AG, et al. Resolution of the expert council «Possibilities of neuroprotective therapy in patients with arterial hypertension and cognitive disorders». Russian Journal of Preventive Medicine. 2024;27(11):85-93. (In Russ.). https://doi.org/10.17116/profmed20242711185